FY2029 EPS Estimates for Journey Medical Boosted by B. Riley

Journey Medical Corporation (NASDAQ:DERM) – Analysts at B. Riley boosted their FY2029 earnings per share estimates for shares of Journey Medical in a research note issued on Thursday, November 13th. B. Riley analyst M. Mamtani now anticipates that the company will post earnings of $0.93 per share for the year, up from their prior estimate of $0.85. The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share.

Journey Medical (NASDAQ:DERM) last issued its earnings results on Wednesday, November 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). Journey Medical had a negative return on equity of 42.71% and a negative net margin of 14.58%.The firm had revenue of $17.63 million during the quarter, compared to analyst estimates of $18.85 million.

Several other equities research analysts also recently weighed in on the stock. Lake Street Capital lifted their price target on shares of Journey Medical from $9.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, August 13th. HC Wainwright initiated coverage on shares of Journey Medical in a report on Monday, August 25th. They set a “buy” rating and a $13.00 price target on the stock. Zacks Research upgraded shares of Journey Medical from a “strong sell” rating to a “hold” rating in a research note on Monday, October 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Journey Medical in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $12.17.

Journey Medical Trading Down 2.7%

Shares of Journey Medical stock traded down $0.21 during midday trading on Friday, reaching $7.48. The company had a trading volume of 143,313 shares, compared to its average volume of 124,969. The firm has a market cap of $196.83 million, a PE ratio of -21.47 and a beta of 0.80. Journey Medical has a fifty-two week low of $3.54 and a fifty-two week high of $9.40. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.27 and a quick ratio of 0.95. The stock has a fifty day moving average price of $7.63 and a 200 day moving average price of $7.32.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Journey Medical in the 2nd quarter valued at about $29,000. Bank of America Corp DE increased its position in shares of Journey Medical by 4,707.0% in the second quarter. Bank of America Corp DE now owns 4,134 shares of the company’s stock worth $30,000 after purchasing an additional 4,048 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Journey Medical in the 2nd quarter worth approximately $36,000. JPMorgan Chase & Co. purchased a new position in Journey Medical in the 2nd quarter worth approximately $41,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Journey Medical during the 2nd quarter valued at $48,000. Institutional investors own 7.25% of the company’s stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.